Empatica has unveiled EmbraceMini, the world’s smallest wrist-worn actigraphy device, designed to revolutionize the clinical trials landscape through unparalleled comfort, data quality, and patient compliance. At just 12mm thick and 14mm wide—comparable to the size of an AA battery—EmbraceMini is purpose-built for passive, non-invasive monitoring of sleep, movement, and other vital parameters. With its sleek, minimalist design, the device eliminates many of the common barriers to wearability in clinical research, particularly in studies requiring long-term participant engagement and reliable adherence.
The EmbraceMini transmits data wirelessly to the FDA-cleared Empatica Health Monitoring Platform, where it is continuously analyzed to extract over 200 digital measures. These include biomarkers related to physical activity, gait, sleep quality, and light exposure—critical indicators for trials in conditions like sleep disorders, depression, obesity, and chronic pain. With a battery life exceeding seven days and the ability to be worn on various body locations, including the wrist, waist, leg, or ankle, EmbraceMini offers researchers exceptional versatility and scalability for decentralized and hybrid clinical trial designs.
The launch of EmbraceMini underscores Empatica’s commitment to patient-centric digital health innovation and its role in modernizing how data is collected and interpreted in real-world studies. By combining medical-grade precision with a form factor that blends seamlessly into daily life, EmbraceMini enables more accurate, consistent, and patient-friendly monitoring. This innovation not only supports the advancement of evidence generation for novel therapies but also strengthens the foundation of remote and personalized care—ushering in a new era of smarter, tech-enabled clinical research.
MedTech Spectrum's Summary
Breakthrough in Wearability for Clinical Research: EmbraceMini is the world’s smallest wrist-worn actigraphy device, offering a compact, lightweight, and discreet design that enhances patient comfort and compliance in long-term clinical trials.
High-Quality, Multi-Modal Data Collection: The device passively captures over 200 digital biomarkers related to sleep, activity, gait, and light exposure, enabling more accurate and continuous monitoring for conditions such as sleep disorders, obesity, and depression.
Advancing Remote and Patient-Centric Trials: With seamless integration into Empatica’s FDA-cleared Health Monitoring Platform and compatibility with existing trial systems via Cloud API, EmbraceMini empowers decentralized trials and marks a significant step toward smarter, more personalized digital health research.
